JP2024511881A - ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物 - Google Patents

ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物 Download PDF

Info

Publication number
JP2024511881A
JP2024511881A JP2023560997A JP2023560997A JP2024511881A JP 2024511881 A JP2024511881 A JP 2024511881A JP 2023560997 A JP2023560997 A JP 2023560997A JP 2023560997 A JP2023560997 A JP 2023560997A JP 2024511881 A JP2024511881 A JP 2024511881A
Authority
JP
Japan
Prior art keywords
dimethyl
cyclopropyl
hexane
azabicyclo
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511881A5 (https=
Inventor
スチュアート コングリーブ マイルズ
アンドリュー クリストファー ジョン
ピックワース マーク
デ グラーフ クリス
ペレツ ヒギュールエロ アリシア
スティーブン メイソン ジョナサン
Original Assignee
ヘプタレス セラピューティクス リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2104742.8A external-priority patent/GB202104742D0/en
Priority claimed from GBGB2107026.3A external-priority patent/GB202107026D0/en
Application filed by ヘプタレス セラピューティクス リミティド filed Critical ヘプタレス セラピューティクス リミティド
Publication of JP2024511881A publication Critical patent/JP2024511881A/ja
Publication of JP2024511881A5 publication Critical patent/JP2024511881A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2023560997A 2021-04-01 2022-04-01 ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物 Pending JP2024511881A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2104742.8A GB202104742D0 (en) 2021-04-01 2021-04-01 Sars-Cov-2 MPRO inhibitor compounds
GB2104742.8 2021-04-01
GB2107026.3 2021-05-17
GBGB2107026.3A GB202107026D0 (en) 2021-05-17 2021-05-17 SARS-COV-2 MPRO inhibitor compounds
PCT/GB2022/050836 WO2022208113A1 (en) 2021-04-01 2022-04-01 Sars-cov-2 mpro inhibitor compounds

Publications (2)

Publication Number Publication Date
JP2024511881A true JP2024511881A (ja) 2024-03-15
JP2024511881A5 JP2024511881A5 (https=) 2025-04-09

Family

ID=81307814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560997A Pending JP2024511881A (ja) 2021-04-01 2022-04-01 ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物

Country Status (7)

Country Link
US (1) US20240217930A1 (https=)
EP (1) EP4313305A1 (https=)
JP (1) JP2024511881A (https=)
KR (1) KR20240004275A (https=)
AU (1) AU2022247287A1 (https=)
CA (1) CA3213008A1 (https=)
WO (1) WO2022208113A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
GB202214644D0 (en) * 2022-10-05 2022-11-16 Heptares Therapeutics Ltd Sars-cov-2 mpro inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504404A (ja) * 2000-07-21 2004-02-12 シェリング・コーポレーション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP2005524628A (ja) * 2002-01-18 2005-08-18 シェーリング　コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4146267A1 (en) * 2020-05-08 2023-03-15 The Board of Trustees of the Leland Stanford Junior University Protease inhibitors for treatment or prevention of coronavirus disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004504404A (ja) * 2000-07-21 2004-02-12 シェリング・コーポレーション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド
JP2005524628A (ja) * 2002-01-18 2005-08-18 シェーリング　コーポレイション Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としての新規ペプチド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL PHYSICS LETTERS, vol. 770, JPN6026005645, 10 February 2021 (2021-02-10), pages 138446, ISSN: 0005797114 *

Also Published As

Publication number Publication date
EP4313305A1 (en) 2024-02-07
KR20240004275A (ko) 2024-01-11
US20240217930A1 (en) 2024-07-04
WO2022208113A1 (en) 2022-10-06
AU2022247287A1 (en) 2023-11-09
CA3213008A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
US20220259145A1 (en) Sars-cov-2 main protease inhibitors
JP2024511881A (ja) ＳＡＲＳ－ＣＯＶ－２ Ｍｐｒｏ阻害剤化合物
EP4263502B1 (en) Sars-cov-2 mpro inhibitor compounds
US12060333B2 (en) Aminocarbamoyl compounds for the treatment of viral infections
TW202330513A (zh) )抑制劑及其使用方法
JP2025533154A (ja) ＳＡＲＳ－ＣＯＶ－２Ｍｐｒｏ阻害剤及びその使用
JP2025003508A (ja) 抗ウイルス１，３－ジ－オキソ－インデン化合物
EP4216961A1 (en) Compositions and methods for treatment of coronavirus infection
JPH07500604A (ja) 高血圧治療用エチルアラニンアミノジオール化合物
CN107074771B (zh) 可溶性环氧化物水解酶抑制剂及其用途
WO2024089159A1 (en) Main protease inhibitors
EP4587433A1 (en) 3-(1h-indole-2-carbonyl)-6,6-dimethyl-n-((s)-1-oxo-3-((s)-2-oxopyrrolidin-3-yl)p ropan-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide derivatives as mpro inhibitors for the treatment of coronavirus infections
CN117858867A (zh) Sars-cov-2 mpro抑制剂化合物
US20250051283A1 (en) Therapeutic compounds and methods
CN117136178A (zh) SARS-COV-2 Mpro抑制剂化合物
EP1768665B1 (en) Peptidomimetic inhibitors of hiv protease
HK40094156B (en) Sars-cov-2 mpro inhibitor compounds
HK40094156A (en) Sars-cov-2 mpro inhibitor compounds
CN120923575A (zh) 一类拟肽类蛋白酶抑制剂及其应用
WO2025071482A1 (en) 3cpro inhibitors and methods thereof
CA2267657A1 (en) Hydroxyphenyl derivatives with hiv integrase inhibitory properties

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260217